Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
The diagnosis and treatment of depression in the elderly population with type 2 diabetes are essential for managing dementia risks.
Read More »Diabetes, Depression, and Dementia Link
Using Semaglutide and Liraglutide To Protect the Kidney?
A two-for-one deal: both cardiovascular benefits and renal protection.
Read More »DKA Leads to Changes in Children’s Cognitive Function
Just one incident of DKA could potentially damage memory in children with type 1 diabetes.
Read More »Glycemic and Adiposity Benefits with Metformin Use in Pregnancy
A placebo-controlled trial was conducted to determine fetal, neonatal, and maternal outcomes associated with metformin use during pregnancy in women with T2DM.
Read More »Left Ventricular Mass Reduction and Empagliflozin
Empagliflozin significantly lowered LVMi, systolic blood pressure, and diastolic blood pressure in patients with CAD and type 2 diabetes.
Read More »Ethnicity Can Affect Risk for Diabetes Complications
A diabetes patient’s risk for chronic kidney disease or cardiovascular disease can be impacted by various factors, including ethnic background.
Read More »Empagliflozin Benefit in Heart Failure, With or Without Diabetes
Studies of empagliflozin and dapagliflozin have shown to reduce cardiovascular risk, indicating a class effect for heart failure patients.
Read More »Using SGLT-2 Inhibitors to Significantly Reduce AFib
Diabetes causes metabolic changes that promote oxidative stress within the heart, resulting in changes that can impede its electrical signaling.
Read More »Analysis of Sotagliflozin’s Effect on Cardiorenal Factors for Type 1 Patients
Can use of the sodium-glucose cotransporter 1 and sodium-glucose cotransporter 2 dual inhibitor in patients with type 1 diabetes preserve kidney function?
Read More »Down Syndrome Youth Have a High Prevalence of Dyslipidemia and Prediabetes
Two-thirds of youth with Down syndrome have a BMI percentile at or above 85, but is this a marker for prediabetes and dyslipidemia in this population?
Read More »